Uncoupling GIP from GLP-1: Long-Acting GIPR Agonist LY3537021 Demonstrates Independent Efficacy in Weight Loss and Glycemic Control
Posted inDiabetes & Endocrinology Internal Medicine news

Uncoupling GIP from GLP-1: Long-Acting GIPR Agonist LY3537021 Demonstrates Independent Efficacy in Weight Loss and Glycemic Control

This Phase 1 study reveals that LY3537021, a long-acting GIPR agonist, independently drives significant weight loss and improves glucose regulation with a favorable safety profile and a 12-day half-life, clarifying the distinct therapeutic role of GIP in metabolic disease management.
Addressing the Human Element: Why Psychological Barriers and Educational Gaps Limit the Efficacy of Diabetes Decision Support Systems
Posted inDiabetes & Endocrinology news Psychiatry

Addressing the Human Element: Why Psychological Barriers and Educational Gaps Limit the Efficacy of Diabetes Decision Support Systems

A randomized trial reveals that while automated decision support systems show marginal overall glycemic benefits in type 1 diabetes, personalized informative feedback significantly aids users with lower baseline knowledge. Success depends heavily on addressing diabetes-related distress and hypoglycemia worry.
GLP-1 Receptor Agonists Associated with Lower Atrial Fibrillation Recurrence After Catheter Ablation in Obese Patients
Posted inCardiology Diabetes & Endocrinology news

GLP-1 Receptor Agonists Associated with Lower Atrial Fibrillation Recurrence After Catheter Ablation in Obese Patients

This real-world study demonstrates that GLP-1 receptor agonists significantly reduce AF recurrence, progression to permanent AF, and cardiovascular hospitalizations in obese patients following catheter ablation, highlighting their role as a critical adjunctive therapy in metabolic-arrhythmic management.
Can We Predict Who Benefits? Baseline Insulin Secretion as a Gatekeeper for Abatacept Efficacy in Stage 1 T1D
Posted inDiabetes & Endocrinology Internal Medicine news

Can We Predict Who Benefits? Baseline Insulin Secretion as a Gatekeeper for Abatacept Efficacy in Stage 1 T1D

A post-hoc analysis demonstrates that baseline insulin secretion identifies responders to abatacept in Stage 1 T1D. High-secretors experienced a 15.8-month delay in disease progression and a 54% reduction in risk, providing the first evidence of successful immune intervention in the earliest stage of the disease.
Haptoglobin 1-1 and Low Protein Levels: Identifying the Lowest Cardiovascular Risk in Type 2 Diabetes
Posted inCardiology Diabetes & Endocrinology news

Haptoglobin 1-1 and Low Protein Levels: Identifying the Lowest Cardiovascular Risk in Type 2 Diabetes

A FIELD sub-study reveals that while higher haptoglobin levels increase cardiovascular risk—particularly in those with the HP 1-1 phenotype—fenofibrate's protective effects remain consistent regardless of haptoglobin status, challenging previous assumptions about phenotype-specific treatment responses.